GMA is the global / international marketing agency lens on this topic. The article connects the issue to market-entry marketing: buyer proof, website language, localization, AI visibility, paid channels, distributor handoff, and sales material in the target market.
MDR Class IIb in place. TÜV Süd notified body engaged. CE-mark renewed. ISO 13485 current. The German medtech CEO assumes the bridge is shorter than it is. The bridge has four FDA-side pathways, a US clinical-evidence layer, a US KOL architecture, a US payer-coding map, and a US IDN procurement buyer who judges everything in US-legible commercial form. The regulatory pathway is FDA counsel. The commercial bridge is the marketing work.
The German medtech operator typically holds a CE-marked device under MDR, ISO 13485 quality-management certification, multi-year European hospital references, and a notified-body relationship (TÜV Süd, TÜV Rheinland, BSI, DEKRA, MDC). Names that fit the archetype: Siemens Healthineers (electromedical lines), Brainlab, Karl Storz, Richard Wolf, Aesculap under B. Braun, Biotronik, Otto Bock, Carl Zeiss Meditec, Drägerwerk. Many also have a smaller-cap cohort of family-controlled medtech specialists across Bavaria, Baden-Württemberg, and NRW.
The US bridge is incomplete for most of the cohort. The FDA pathway is selected, partially executed, or pending. US clinical evidence is partial. US KOL relationships exist transactionally rather than as architecture. US payer and reimbursement positioning is under-resourced. US IDN procurement buyers are unfamiliar with the device. Per GTAI tracking, German medtech exports to North America in 2025-2026 remain at multi-year highs, while US clinical-evidence presence remains below where the export volume would suggest.
The MDR-to-FDA bridge has a regulatory side and a commercial side. FDA counsel handles the pathway. Marketing handles the website, deck, and sales material. Both sides need to ship together.
MDR (Regulation EU 2017/745) governs CE-marking in the EU and replaced the prior MDD framework, raising evidentiary requirements, tightening post-market surveillance, and introducing the European Database on Medical Devices (Eudamed). None of this satisfies the FDA.
A German medtech firm with a Class IIb CE-marked device under MDR has not satisfied the FDA. The FDA judges US predicate, US classification, US clinical evidence, US post-market surveillance. The MDR clinical evaluation report does not auto-port to FDA clinical-data acceptability. The German firm's sales story in the US must surface the FDA pathway, the named timeline, and the US clinical-evidence position in US-legible form so US health-system procurement and KOL conversations can proceed in parallel with the regulatory submission.
Pathway selection is FDA regulatory counsel work. The marketing work is to surface the selected pathway, the named timeline, and the US clinical-evidence position in the US-facing materials so the US procurement buyer, the US KOL, and the US payer can be brought along in parallel with the submission.
"MDR Class IIb means cleared in the EU. FDA judges US predicate, US classification, US clinical evidence, US post-market. The bridge is two regimes."House view on MDR-to-FDA crossing
ISO 13485 is the international medical-device quality-management standard. FDA QSR under 21 CFR Part 820 is the US regulatory requirement. The FDA has finalised harmonisation moving 21 CFR Part 820 toward ISO 13485, but with US-specific overlays that include unique device identification, complaint handling, and US-specific reporting. ISO 13485 supports but does not equal FDA QSR.
The German medtech firm's ISO 13485 certification supports FDA preparation. It does not substitute for QSR-specific compliance work. The compliance gap analysis, the QSR alignment plan, and the FDA pre-approval inspection strength all sit with FDA regulatory counsel and quality-systems specialists. The marketing surface flags the ISO 13485 baseline and the QSR alignment work openly, so the US procurement buyer is not surprised.
FDA clearance is the gate. The US commercial bridge is the work on the gate that marketing actually owns.
| Before rebuild (MDR-leading register) | After rebuild (US-commercial-fit) |
|---|---|
| CE-mark and MDR class lead the materials | FDA pathway, named timeline, US clinical-evidence plan at the front |
| European hospital references in the lead | US IDN and US clinical-investigator references in the lead where they exist; honest pilot stage where they do not |
| European clinical-evaluation report referenced | US clinical-evidence plan named, US trial sites named, US PI engagement named |
| European KOL endorsement (DGCH, DGOOC, etc.) | US KOL architecture: named US opinion leaders, named US academic medical centers, US society memberships |
| European reimbursement, DRG referenced | US reimbursement: CMS CPT, HCPCS, ICD-10-PCS, MS-DRG mapping |
| EUR pricing, European warranty | USD pricing, US warranty in US-legible form, US service-footprint commitments |
US IDN procurement (HCA Healthcare, CommonSpirit, Ascension, Mass General Brigham, Cleveland Clinic, Kaiser, Mayo, UPMC) and US GPO procurement (Vizient, Premier, HealthTrust, Intalere) evaluate the materials against FDA clearance, US clinical evidence, US KOL endorsement, US service footprint, and US reimbursement coding. The German medtech firm without US clinical evidence and without US-coded reimbursement carries gaps the GPO RFP cannot ignore. The fix is to surface US clinical-evidence development plans, US KOL relationships under construction, and US reimbursement positioning in US-legible commercial terms even where the work is in progress.
Stage one: evaluation where the bridge breaks. Regulatory pathway selection. Clinical-evidence portability. US payer positioning. US KOL architecture. US IDN procurement strength. Where GMA is in each.
Stage two: correct the signal. Surface the FDA pathway, named timeline, US clinical-evidence plan, US KOL relationships under construction, US payer and reimbursement positioning. Move MDR and CE-mark to supporting context. Move European references and DRG to supporting context.
Stage three: rebuild the materials. US-facing site, US-procurement-facing materials for IDN and GPO, US KOL-facing materials, US payer-facing materials, US sales-cycle templates, US service-footprint commitments, US-facing owner page with US clinical-affairs counterpart.
This work runs inside a Market-Entry Marketing Sprint (six to ten weeks, one US IDN target and the US-facing materials shipped), a Cross-Border Marketing Build (three to six months, multi-architecture rebuild across IDN, GPO, KOL, and payer), or a Global Marketing Partnership (monthly retainer, twelve-month minimum, for medtech groups with multiple device lines). Pricing is discussed after GMA sees the company, market, and work needed.
"510(k) submissions accounted for the majority of FDA medical-device clearances. De Novo and PMA pathways carry materially longer timelines and additional clinical-evidence requirements. The Q-Submission programme is available for pre-submission feedback at any stage."
Independent regimes. MDR EU 2017/745 governs CE-marking. FDA pathways are 510(k), De Novo, PMA, or IDE-PMA. ISO 13485 supports but does not equal FDA QSR. MDR clinical evidence does not auto-port to FDA acceptability.
ISO 13485 is the international medical-device QMS standard. QSR is the US regulatory requirement. The FDA is harmonising 21 CFR Part 820 toward ISO 13485 with US-specific overlays. ISO 13485 supports but does not equal QSR.
510(k) on a US predicate. De Novo for novel low-to-moderate risk. PMA for Class III. IDE-then-PMA when a significant-risk clinical study is needed. Pathway selection is FDA regulatory counsel work.
No. FDA 510(k) and PMA submissions, De Novo, IDE applications, Q-Submission filings, FDA QSR compliance, MDUFA fee filings, ISO 13485 audits, MDR clinical evaluation reports, and notified-body engagement belong with FDA regulatory counsel and notified-body specialists.
US category positioning, US clinical-evidence narrative, US KOL architecture, US payer and reimbursement positioning, US IDN and GPO procurement frame, US-facing site, materials, bios, and commercial cadence.
Evaluate where the bridge breaks. Correct the signal: surface the FDA pathway, named timeline, US clinical-evidence plan, US KOL relationships, US payer and reimbursement positioning. Rebuild the materials.
Designation under FDARA Section 3051 provides expedited evaluation and increased FDA engagement for life-threatening or irreversibly debilitating conditions. Accelerates timelines. Does not change classification or replace clinical evidence requirements.
Inquiry through the contact form and an inquiry screening. Share the device classification (EU and intended FDA), the FDA pathway counsel has scoped, the US clinical-evidence plan if drafted, US KOL relationships if any, and the US-facing site if any. Response within one business day.
No FDA 510(k) or PMA submissions. No De Novo classification requests. No IDE applications. No Q-Submission filings. No FDA pre-submission meetings. No FDA QSR compliance gap analysis. No FDA pre-approval or post-approval inspections. No 21 CFR Part 11 compliance. No MDUFA fee filings. No ISO 13485 certification audits. No MDR clinical evaluation reports. No EU Notified Body engagement. No CMS reimbursement coding decisions. No US health-system contract negotiation. These belong with FDA regulatory counsel, notified-body specialists, and US reimbursement specialists. When a marketing decision intersects FDA, MDR, ISO 13485, QSR, or US reimbursement, GMA flags and defers.
If the market is not responding, the first question is simple: what is the buyer not seeing, trusting, or doing yet?
| Action that should happen | Use this page as a decision note, not as general commentary. It should answer one market-entry tension. |
| What may be unclear | The tension is that the company may be strong at home while the new-market buyers evaluate the proof, language, channel, price, or follow-up as weak. |
| What to inspect | The consequence is wasted spend, slower pipeline, distributor drift, weak RFQs, or buyers who like the product but do not move. |
| Next step | Use the example on this page to decide whether the next move is more context, /engagements/, or /contact/#inquiry. |